| Literature DB >> 16476947 |
A Tosoni1, G Cavallo, M Ermani, L Scopece, E Franceschi, C Ghimenton, M Gardiman, L Pasetto, V Blatt, A A Brandes.
Abstract
The authors investigated the safety of 75 mg/m2 temozolomide for 21 days every 28 days in glioma patients. This schedule could lead to DNA repair enzyme O6-alkylguanine-DNA alkyltransferase depletion, contributing to overcoming drug resistance. Although Phase III studies are forthcoming, no data are available on the long-term toxicity of temozolomide, which, in this series, incurred prolonged, cumulative lymphopenia, which leads to a high incidence of infections.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16476947 DOI： 10.1212/01.wnl.0000196465.83423.ec
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910